ReportWire

Tag: cardiovascular

  • There's No Heightened Cardiovascular Danger with Cannabis Use, Study Indicates | High Times

    There's No Heightened Cardiovascular Danger with Cannabis Use, Study Indicates | High Times

    According to a study published in the journal Heart Rhythm, middle-aged adults who have a history of using cannabis are not at an elevated risk of experiencing atrial fibrillation (AFib), aka an irregular heartbeat, NORML reports. The relationship between cannabis and heart disease is currently under close scrutiny and attention. 

    This longitudinal study was conducted by researchers at the University of California, San Francisco. The team looked at the connection between cannabis use and AFib in a very large sample size, a group of over 150,000 individuals aged between 40 and 69. This group of people was made up of people who didn’t use cannabis, occasional users, and frequent cannabis users. They monitored participants over six years. The findings reveal no significant evidence suggesting that people who used cannabis had a bigger chance of developing atrial fibrillation compared to non-users.

    “Among a large, prospective cohort, we were unable to find evidence that occasional cannabis use [defined as more than 100 times] was associated with a higher risk of incident AF,” the study writes. “To our knowledge, this is the first longitudinal cohort study to assess such recreational use and the first to report an absence of a relationship between cannabis use and risk of AF.”

    AFib is a heart rhythm disorder identifiable by a rapid and irregular beat of the heart’s upper chambers, aka the atria. This arrhythmia can cause disruptive, settling, and potential dangerous symptoms like heart palpitations, shortness of breath, fatigue, dizziness, or chest pain. Some people may not experience any symptoms at all. AFib is dangerous because it increases the risk of blood clots forming in the heart. These can then develop into strokes. Over time, AFib may also weaken the heart, which could result in heart failure. Before you panic and have an anxiety attack that you mistake for AFib, know that it needs to be diagnosed by a doctor and is done so using electrocardiograms (ECGs). The treatment for AFib is focused on controlling the heart rate to return to a normal heart rhythm using medications or medical interventions, in addition to lifestyle changes. 

    As NORML reports, in October, research findings suggested that middle-aged folks who use weed don’t have a higher risk of atherosclerosis, aka which is the hardening of the arteries, compared to those who have never used cannabis. This conclusion was backed up by a meta-analysis published in May, concludeding, “Cannabis use insignificantly predicts all major cardiovascular adverse events,” referring to conditions like myocardial infarction and stroke. However, at times, the data is conflicting. A contrasting report from September of 2024 in the journal Addiction highlighted that adults involved in problematic cannabis use do have a heightened risk of adverse cardiovascular outcomes. 

    As High Times reported, the research analyzed medical data from nearly 60,000 adults in Alberta, Canada. It specifically looked at diagnostic codes for “cannabis use disorder,” keep in mind, this is a publication with a focus on addiction. As High Times reported, they define cannabis use disorder as an inability to cease cannabis use despite negative consequences. 

    They compared these with codes for various cardiovascular issues, including heart attacks, heart failure, and strokes, occurring between January 1, 2012, and December 31, 2019.

    The study’s findings were a bit alarming: “Canadian adults with cannabis use disorder appear to have an approximately 60% higher risk of experiencing incident adverse cardiovascular disease events than those without cannabis use disorder,” it reported. “Importantly, this evidence suggests that cannabis use may place a healthier population at increased risk of major cardiovascular events. As a result, our study points to the importance of educating our patients about the potential risks associated with cannabis use and cannabis use disorder,” reads the study. 

    It additionally revealed that people diagnosed with cannabis use disorder who were otherwise deemed ‘healthy’ (having no co-occurring mental health disorders, doctor visits in the past six months, prescribed meds, or no other medical conditions) were at a greater risk for these cardiovascular events.

    But, to end on a more reassuring note, know that this too has conflicting evidence. Research published in August of 2023 in the American Journal of Cardiology indicates that middle-aged adults using cannabis are not at an increased risk of heart attack. The study, which compared people who used cannabis with non-cannabis users, found that individuals who consumed it monthly over the past year did not face a heightened risk of heart attack.  

    Sophie Saint Thomas

    Source link

  • CorMatrix Cardiovascular Secures Fifty-Six (56) Patents in 2016 Expanding Patent Protect for Extracellular Matrix (ECM®) Based Implantable Devices

    CorMatrix Cardiovascular Secures Fifty-Six (56) Patents in 2016 Expanding Patent Protect for Extracellular Matrix (ECM®) Based Implantable Devices

    Press Release



    updated: Jan 19, 2017

    ​CorMatrix® Cardiovascular, Inc., (www.cormatrix.com) a leading developer of biomaterial compositions and medical devices for regenerative medicine, today announced the issuance of 56 patents in 2016.  The ongoing expansion of this patent portfolio continues to support the Company’s development of novel extracellular matrix (ECM®) based devices and compositions.

    Of the fifty-six patents, 19 were obtained internationally. CorMatrix currently holds 13 trademarks related to its Extracellular Matrix products and the Company has secured some 128 patents affording significant intellectual property protection in the area of regenerative medicine. CorMatrix ECM is a naturally occurring bioscaffold that remodels over time into healthy, organized tissue that is site specific.

    CorMatrix’s intellectual property portfolio is outstanding. We have very comprehensive coverage of not only the ECM devices we provide to our core markets, but also of the innovations that can find applications in other important areas of regenerative medicine.

    Dr. Robert Matheny, Chief Scientific Officer, CorMatrix Cardiovascular, Inc.

    “CorMatrix’s intellectual property portfolio is outstanding. We have very comprehensive coverage of not only the ECM devices we provide to our core markets, but also of the innovations that can find applications in other important areas of regenerative medicine,” said Robert Matheny, MD, CSO of CorMatrix. “From the beginning, we recognized the importance of developing and then protecting our technology. As a pioneer in the field of regenerative science since 2001, having our patents recognized by offices around the globe (United States, Europe, South America, Australia and others) is a source of pride for the entire Company, our Partners, and our Investors.”

    Extracellular matrix has been used as a biologic scaffold in many different surgical applications including cardiac and vascular repairs, pelvic floor reconstructions, dental surgery, and veterinary medicine to identify a few. A steady production of both preclinical and clinical data support the need for organs and tissues to have an inductive scaffold for the cells, particularly stem cells, to be retained, restored, and to function normally.

    Among the patents issued this year, CorMatrix secured US 9,352,070 for use as a tissue prosthesis which can be engineered into a variety of shapes and used to repair, reconstruct or replace damaged or diseased tissue and the associated biological structures. This includes seamless tubular uses (for vein and arterial replacements), heart valves, myocardium, pericardium and other significant aortic structures. Use of ECM as a prosthetic also could also be extended to esophageal, tracheal, and bronchial anatomy. The Company currently has 510(k) clearances for their implantable ECM devices used in adult and pediatric cardiac tissue repair, pericardial reconstruction, and vascular repair.

    Two additional patents, US 8,980,296 and US 8,877,224; along with the issuance of European patent No. 2398502, may significantly address issues surrounding the prevention, reduction, and treatment of myocardial damage and arrhythmic sequelae. Atrial fibrillation, (AFib or AF) is the most common type of heart arrhythmia and affects an estimated 3-6 million people in the United States. More than 750,000 hospitalizations occur each year because of AFib and cost the United States approximately $6 billion each year. Through these patents, micronized extracellular matrix (with or without stem cells) is delivered via intra-myocardial injection into the area of infarct enabling regrowth and restoration of the native cardiac function. Medical costs for people with AFib are almost $9K higher per year than for people who do not have AFib.1, 2  

    “Our CorMatrix technology backed by the Company’s patents is harnessing the potential of stem cells and matrix factors working together to regenerate site specific tissue,” said Andrew Green, CEO of CorMatrix.  “We now have preclinical and human evidence of regenerating heart muscle after myocardial infarctions and myocardial tissue replacement treatments. No other company, stem cell based or otherwise, has been able to demonstrate this concept. Now our goal is to make it available around the world.”

    About CorMatrix

    CorMatrix® Cardiovascular, Inc. is a privately held medical device company dedicated to developing and delivering innovative biomaterial devices that harness the body’s own innate ability to repair damaged cardiac and vascular tissues.  CorMatrix ECM Technology allows surgeons to restore the native anatomy of cardiac and vascular tissue in need of repair, serving as a superior alternative to synthetic or cross-linked materials. Headquartered in Roswell, Georgia, the Company is currently researching, developing, and commercializing a platform technology known as CorMatrix® ECM® for a variety of cardiovascular and other indications, and has U.S. clearance and European registration (with a CE Mark) for its ECM® technology.  Since its launch in 2006, CorMatrix® ECM® Technology has been used at more than 1000 hospitals across the U.S. and has been implanted in over 145,000 cardiovascular procedures.  Visit cormatrix.com for additional information.

    1 January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Journal of the American College of Cardiology. 2014; 64(21):2246–80.

    2Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015; 131:e29–e322.

    Source: CorMatrix Cardiovascular, Inc.

    Source link